Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 8/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555663 | 0.80 | FGFR1 (0.47) | FGFR1TBXA2RPLA2G4AMEN1TP53 | |
| SCHEMBL30497306 | 0.80 | FGFR1 (0.47) | FGFR1TBXA2RPLA2G4AMEN1TP53 | |
| SCHEMBL30497324 | 0.79 | FGFR1 (0.54) | FGFR1TBXA2RMEN1TP53PABPC1 | |
| SCHEMBL30497301 | 0.78 | FGFR1 (0.56) | FGFR1TBXA2RPLA2G4AMEN1TP53 | |
| SCHEMBL1608848 | 0.78 | CYP11B1 (0.60) | FGFR1MEN1TP53PABPC1KMT2A | |
| SCHEMBL30497328 | 0.78 | FGFR1 (0.47) | FGFR1TBXA2RPLA2G4AMEN1TP53 | |
| SCHEMBL29555429 | 0.78 | FGFR1 (0.47) | FGFR1TBXA2RPLA2G4AMEN1TP53 | |
| SCHEMBL30497287 | 0.77 | FGFR1 (0.49) | FGFR1TBXA2RPLA2G4AMEN1TP53 | |
| SCHEMBL3838757 | 0.76 | FGFR1 (0.56) | FGFR1TBXA2RPLA2G4AMEN1KMT2A | |
| SCHEMBL13508660 | 0.75 | CYP11B1 (0.57) | FGFR1TBXA2RPLA2G4AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | FGFR1 987/4885TBXA2R 66/4885PLA2G4A 971/4885 |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | FGFR1 987/4885TBXA2R 66/4885PLA2G4A 971/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | FGFR1 987/4885TBXA2R 66/4885PLA2G4A 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.